Royal Bank Of Canada Reaffirms “Sector Perform” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reiterated by research analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $737.00 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential downside of 2.30% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Truist Financial increased their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $802.18.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $3.83 during midday trading on Tuesday, reaching $754.34. 163,629 shares of the company’s stock traded hands, compared to its average volume of 826,752. Regeneron Pharmaceuticals has a 52-week low of $541.00 and a 52-week high of $859.34. The stock has a market cap of $77.67 billion, a P/E ratio of 18.63, a PEG ratio of 1.47 and a beta of 0.20. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average is $782.91 and its 200 day moving average is $720.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the company earned $12.81 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,146 shares of company stock worth $3,432,488 in the last 90 days. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of REGN. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $5,682,636,000. Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after buying an additional 835,240 shares during the last quarter. Legal & General Group Plc acquired a new position in Regeneron Pharmaceuticals in the second quarter worth $473,872,000. Bank of New York Mellon Corp acquired a new position in Regeneron Pharmaceuticals in the second quarter worth $472,950,000. Finally, Deutsche Bank AG acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $323,249,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Zacks upgraded Regeneron from “hold” to “strong buy,” providing a significant sentiment boost and signaling confidence in the stock’s valuation and earnings outlook. Zacks upgrade
• Positive Sentiment: Sell-side analysts collectively rate REGN “moderate buy,” suggesting that broader analyst sentiment remains favorable despite recent volatility. Analyst rating summary
• Positive Sentiment: Biohaven has begun enrolling patients in a combination study pairing BHV-1530 with Regeneron’s cancer drug Libtayo. The agreement could support additional clinical evidence and potential long-term collaboration revenue, although it is not an immediate earnings driver. Biohaven and Libtayo agreement

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.